Literature DB >> 20613895

Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Karin K Shih1, Dennis S Chi.   

Abstract

The surgical management of advanced epithelial ovarian cancer involves cytoreduction, or removal of grossly-evident tumor. Residual disease after surgical cytoreduction of ovarian cancer has been shown to be strongly associated with survival. The goal of surgery is "optimal" surgical cytoreduction, which is generally defined as residual disease of 1 cm or less. However, the designation of "optimal" surgical cytoreduction has evolved to include maximal surgical effort and no gross residual disease. In order to achieve this, more aggressive surgical procedures such as rectosigmoidectomy, diaphragm peritonectomy, partial liver resection, and video-assisted thoracic surgery are reported and increasingly utilized in the surgical management of advanced ovarian cancer. The role of maximal surgical effort also extends to the recurrent setting where the goal of surgery should be complete cytoreduction. Patient selection is important in identifying appropriate candidates for surgical cytoreduction in the recurrent setting. The purpose of this article is to review the role of maximum surgical effort in primary and recurrent ovarian cancer.

Entities:  

Keywords:  Cytoreduction; Ovarian cancer

Year:  2010        PMID: 20613895      PMCID: PMC2895720          DOI: 10.3802/jgo.2010.21.2.75

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  57 in total

1.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

Authors:  S M Eisenkop; R L Friedman; N M Spirtos
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

2.  Survival of patients following secondary cytoreductive surgery in ovarian cancer.

Authors:  J S Berek; N F Hacker; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-02       Impact factor: 7.661

3.  En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEMH experience.

Authors:  J.E. Bridges; Y. Leung; I.G. Hammond; A.J. McCartney
Journal:  Int J Gynecol Cancer       Date:  1993-07       Impact factor: 3.437

4.  Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.

Authors:  A R Munkarah; A V Hallum; M Morris; T W Burke; C Levenback; E N Atkinson; J T Wharton; D M Gershenson
Journal:  Gynecol Oncol       Date:  1997-01       Impact factor: 5.482

5.  Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.

Authors:  Giovanni D Aletti; Karl C Podratz; Monica B Jones; William A Cliby
Journal:  J Am Coll Surg       Date:  2006-08-23       Impact factor: 6.113

6.  The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions.

Authors:  Margrit M Juretzka; Nadeem R Abu-Rustum; Yukio Sonoda; Robert J Downey; Raja M Flores; Bernard J Park; Martee L Hensley; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2006-12-05       Impact factor: 5.482

7.  The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Authors:  Oliver Zivanovic; Eric L Eisenhauer; Qin Zhou; Alexia Iasonos; Paul Sabbatini; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2007-11-13       Impact factor: 5.482

8.  Tertiary cytoreduction in patients with recurrent ovarian carcinoma.

Authors:  Mario M Leitao; Steven Kardos; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

9.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

10.  Secondary cytoreduction for ovarian cancer following cisplatin therapy.

Authors:  R A Segna; P R Dottino; J P Mandeli; K Konsker; C J Cohen
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

View more
  46 in total

1.  Circ-EEF2 facilitated autophagy via interaction with mir-6881-3p and ANXA2 in EOC.

Authors:  Min Yong; Jianguo Hu; Hongtao Zhu; Xinwei Jiang; Xiaolin Gan; Lina Hu
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

2.  Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study.

Authors:  Kiran Bagul; D K Vijaykumar; Anupama Rajanbabu; Mitchelle Aline Antony; Venkatesan Ranganathan
Journal:  Indian J Surg Oncol       Date:  2017-02-18

3.  Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma.

Authors:  Jamie N Bakkum-Gamez; Carrie L Langstraat; Janice R Martin; Maureen A Lemens; Amy L Weaver; Sumer Allensworth; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

Review 4.  Gynecological Cancers-the Changing Paradigm.

Authors:  P Rema
Journal:  Indian J Surg Oncol       Date:  2018-11-29

5.  Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Authors:  Neil S Horowitz; G Larry Maxwell; Austin Miller; Chad A Hamilton; Bunja Rungruang; Noah Rodriguez; Scott D Richard; Thomas C Krivak; Jeffrey M Fowler; David G Mutch; Linda Van Le; Roger B Lee; Peter Argenta; David Bender; Krishnansu S Tewari; David Gershenson; James J Java; Michael A Bookman
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

6.  Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.

Authors:  Dina Mury; Linn Woelber; Sabine Jung; Christine Eulenburg; Matthias Choschzick; Isabell Witzel; Joerg Schwarz; Fritz Jaenicke; Sven Mahner
Journal:  J Cancer Res Clin Oncol       Date:  2011-02-23       Impact factor: 4.553

7.  Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.

Authors:  P Cascales Campos; L A Martinez Insfran; D Wallace; J Gil; E Gil; A Gonzalez Gil; J Martínez; J L Alonso Romero; R Gonzalez Sanchez; P Parrilla
Journal:  Clin Transl Oncol       Date:  2019-08-07       Impact factor: 3.405

8.  Surgical technique of visceral segmental serosectomy for advanced ovarian cancer.

Authors:  Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

Review 9.  Splenectomy and distal pancreatectomy in advanced ovarian cancer.

Authors:  Eun Ji Lee; Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

10.  Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Irina Balescu
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.